Did James Inhofe buy CRISPR Therapeutics stock?

Common questions

Did James Inhofe buy CRISPR Therapeutics stock?

Yes. James Inhofe disclosed 1 purchase and 3 sales of CRISPR Therapeutics (CRSP) stock between Oct 19, 2017 and Jan 5, 2021, in STOCK Act reports. Added together, the disclosed purchases come to $15K-$50K and the disclosed sales to $66K-$165K.

How big were James Inhofe's CRISPR Therapeutics trades?

STOCK Act reports give a range for each trade, such as $1K-$15K, never an exact amount. Added together, the disclosed purchases come to $15K-$50K and the disclosed sales to $66K-$165K.

Did James Inhofe make these CRISPR Therapeutics trades personally?

Not always. The STOCK Act requires members to report trades by themselves, a spouse and dependent children. The owner column of each linked filing says whose trade it was.

Does James Inhofe still own CRISPR Therapeutics stock?

This page lists reported trades, not holdings. A purchase can have been sold since, and the filings shown do not say what is held today.

When did James Inhofe report these trades?

The latest filing is dated Jan 15, 2021. The STOCK Act gives members of Congress 45 days to report a trade, so a filing can trail the trade by weeks. Every row shows both dates.

Where does this data come from?

From periodic transaction reports filed under the STOCK Act with the Secretary of the Senate. Every trade links to the original filing.